Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon
Open Access
- 4 June 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (3), 514-516
- https://doi.org/10.1093/infdis/jiaa314
Abstract
Liza Dawson, PhD, MA, Jake Earl, PhD, Jeffrey Livezey, MD, MSc, LTC, MC, USA; SARS-CoV-2 Human Challenge Trials: Too Risky, Too Soon, The Journal of InfectiousKeywords
This publication has 20 references indexed in Scilit:
- Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection WithVibrio choleraeO1 El TorClinical Infectious Diseases, 2016
- On the Alleged Right to Participate in High-Risk ResearchBioethics, 2015
- Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax MalariaThe New England Journal of Medicine, 2013
- Development of the RTS,S/AS malaria candidate vaccineVaccine, 2009
- Limits to research risksJournal of Medical Ethics, 2009
- Trust in Health Research Relationships: Accounts of Human SubjectsJournal of Empirical Research on Human Research Ethics, 2008
- Exploiting a Research Underclass in Phase 1 Clinical TrialsThe New England Journal of Medicine, 2008
- Preventive Misconception: Its Nature, Presence, and Ethical Implications for ResearchAmerican Journal of Preventive Medicine, 2007
- Central Challenges Facing the National Clinical Research EnterpriseJAMA, 2003
- Quality of informed consent in cancer clinical trials: a cross-sectional surveyThe Lancet, 2001